These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 3355613)

  • 21. Selective reduction of cholesterol in HDL2 fraction by probucol in familial hypercholesterolemia and hyperHDL2 cholesterolemia with abnormal cholesteryl ester transfer.
    Matsuzawa Y; Yamashita S; Funahashi T; Yamamoto A; Tarui S
    Am J Cardiol; 1988 Jul; 62(3):66B-72B. PubMed ID: 3394656
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative study of bezafibrate and probucol in hyperlipidaemia.
    Páez Moreno JP; González G
    Curr Med Res Opin; 1989; 11(8):523-32. PubMed ID: 2680288
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of probucol on triton induced hyperlipidemias in CFY rats.
    Krishnamurthy A; Thapar GS; Shridhar DR
    Artery; 1985; 13(2):87-94. PubMed ID: 4084069
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Comparative study of the effects of probucol, fenofibrate and clofibrate on liver ultrastructure in rats (author's transl)].
    Barnard SD; Molello JA; Caldwell WJ; Lebeau JE
    Nouv Presse Med; 1980 Oct; 9(40):3005-7. PubMed ID: 7443440
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of probucol on the composition of lipoproteins and on VLDL apoprotein B turnover.
    Lock DR; Kuisk I; Gonen B; Patsch W; Schonfeld G
    Atherosclerosis; 1983 Jun; 47(3):271-8. PubMed ID: 6882500
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of long-term antihypertensive and hypolipidemic treatment on high density lipoprotein cholesterol and apolipoproteins A-I and A-II.
    Miettinen TA; Huttunen JK; Ehnholm C; Kumlin T; Mattila S; Naukkarinen V
    Atherosclerosis; 1980 Jun; 36(2):249-59. PubMed ID: 6773532
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Probucol-lipid pharmacology.
    Kritchevsky D
    Artery; 1982; 10(1):1-6. PubMed ID: 6807261
    [No Abstract]   [Full Text] [Related]  

  • 28. The hypolipidemic action of probucol. Drug transport and lipoprotein composition in type IIa hyperlipoproteinemia.
    Dachet C; Jacotot B; Buxtorf JC
    Atherosclerosis; 1985 Dec; 58(1-3):261-8. PubMed ID: 4091882
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Probucol and ischaemic heart disease.
    Oliver MF
    Lancet; 1981 Oct; 2(8250):805. PubMed ID: 6116924
    [No Abstract]   [Full Text] [Related]  

  • 30. Coronary heart disease, cancer, lipoproteins, and the effects of clofibrate: is enzyme induction a common link and are lipoproteins red herrings?
    Heller RF
    Lancet; 1981 Dec; 2(8258):1258-60. PubMed ID: 6118672
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Comparative effect of probucol and clofibrate in patients with primary hypercholesterolemia].
    Pasquali R; Melchionda N; Parenti M; Cavazzini MG; Biso P; Baraldi G; Sorrenti G; De Benedittis G; Labò G
    Clin Ter; 1982 Dec; 103(5):509-20. PubMed ID: 7160143
    [No Abstract]   [Full Text] [Related]  

  • 32. Intensive combination drug therapy of familial hypercholesterolemia with lovastatin, probucol, and colestipol hydrochloride.
    Witztum JL; Simmons D; Steinberg D; Beltz WF; Weinreb R; Young SG; Lester P; Kelly N; Juliano J
    Circulation; 1989 Jan; 79(1):16-28. PubMed ID: 2642754
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of probucol on cholesterol metabolism in the rat.
    Li JR; Holets RJ; Kottke BA
    Atherosclerosis; 1980 Aug; 36(4):559-65. PubMed ID: 7417372
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of probucol on the in vivo plasma clearance of human low density lipoproteins in rabbits and on the expression of lipoprotein receptors in vitro.
    Trezzi E; Roma P; Bernini F; Fumagalli R; Catapano AL
    Atherosclerosis; 1984 Sep; 52(3):309-16. PubMed ID: 6093829
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Experience with probucol in the treatment of hypercholesterolemia.
    Davignon J; Lussier-Cacan S; Dubreuil-Quidoz S; LeLorier J
    Artery; 1982; 10(1):48-55. PubMed ID: 7092576
    [No Abstract]   [Full Text] [Related]  

  • 36. Inhibition of neutral cholesterol ester hydrolase in rat liver by fibric acids and probucol in vitro.
    Shand JH; West DW
    Biochem Soc Trans; 1994 Nov; 22(4):434S. PubMed ID: 7698452
    [No Abstract]   [Full Text] [Related]  

  • 37. Iatrogenic profound hypoalphalipoproteinaemia: an unrecognised cause of very low HDL cholesterol.
    Murphy MJ; Duncan A; Vallance BD; Packard CJ; O'Reilly DS
    Postgrad Med J; 1995 Aug; 71(838):498-500. PubMed ID: 7567762
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of probucol on plasma lipids and lipoproteins in type IIb hyperlipoproteinemia.
    Hunninghake DB; Bell C; Olson L
    Atherosclerosis; 1980 Nov; 37(3):469-74. PubMed ID: 7458992
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Probucol in hypercholesterolemia. A double blind study.
    Riesen WF; Keller M; Mordasini R
    Atherosclerosis; 1980 Jun; 36(2):201-7. PubMed ID: 7406949
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Probucol and cholestyramine combination in the treatment of severe hypercholesterolemia.
    Sommariva D; Bonfiglioli D; Tirrito M; Pogliaghi I; Branchi A; Cabrini E
    Int J Clin Pharmacol Ther Toxicol; 1986 Sep; 24(9):505-10. PubMed ID: 3781686
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.